{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["7"],"submitter":["Bass TZ"],"pubmed_abstract":["Overexpression of human epidermal growth factor receptor 3 (HER3) is involved in resistance to several therapies for malignant tumours. Currently, several anti-HER3 monoclonal antibodies are under clinical development. We introduce an alternative approach to HER3-targeted therapy based on engineered scaffold proteins, i.e. affibody molecules. We designed a small construct (22.5 kDa, denoted 3A3), consisting of two high-affinity anti-HER3 affibody molecules flanking an albumin-binding domain ABD, which was introduced for prolonged residence in circulation. In vitro, 3A3 efficiently inhibited growth of HER3-expressing BxPC-3 cells. Biodistribution in mice was measured using 3A3 that was site-specifically labelled with <sup>111</sup>In via a DOTA chelator. The residence time of <sup>111</sup>"],"journal":["Scientific reports"],"pagination":["43118"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5322329"],"repository":["biostudies-literature"],"pubmed_title":["In vivo evaluation of a novel format of a bivalent HER3-targeting and albumin-binding therapeutic affibody construct."],"pmcid":["PMC5322329"],"pubmed_authors":["Orlova A","Frejd FY","Mitran B","Tolmachev V","Stahl S","Rosestedt M","Lofblom J","Bass TZ"],"additional_accession":[]},"is_claimable":false,"name":"In vivo evaluation of a novel format of a bivalent HER3-targeting and albumin-binding therapeutic affibody construct.","description":"Overexpression of human epidermal growth factor receptor 3 (HER3) is involved in resistance to several therapies for malignant tumours. Currently, several anti-HER3 monoclonal antibodies are under clinical development. We introduce an alternative approach to HER3-targeted therapy based on engineered scaffold proteins, i.e. affibody molecules. We designed a small construct (22.5 kDa, denoted 3A3), consisting of two high-affinity anti-HER3 affibody molecules flanking an albumin-binding domain ABD, which was introduced for prolonged residence in circulation. In vitro, 3A3 efficiently inhibited growth of HER3-expressing BxPC-3 cells. Biodistribution in mice was measured using 3A3 that was site-specifically labelled with <sup>111</sup>In via a DOTA chelator. The residence time of <sup>111</sup>","dates":{"release":"2017-01-01T00:00:00Z","publication":"2017 Feb","modification":"2026-05-30T06:57:07.393Z","creation":"2019-03-27T02:37:10Z"},"accession":"S-EPMC5322329","cross_references":{"pubmed":["28230065"],"doi":["10.1038/srep43118"]}}